Keryx Biopharmaceuticals (KERX) CEO Buys 71K Shares After Massive Sell-Off
Tweet Send to a Friend
Get Alerts KERX Hot Sheet
Up)
Trade KERX Now!
Keryx Biopharmaceuticals Inc. (Nasdaq: KERX) CEO is trying to instill some confidence in the stock after this week's major sell-off. CEO Ron Bentsur disclosed the purchase of 71,400 shares on 4/4 at $1.3799.
Shares of KERX are down nearly 70% after KRX-0401 + Xeloda did not meet its primary endpoint in a Phase 3 study.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Shares of KERX are down nearly 70% after KRX-0401 + Xeloda did not meet its primary endpoint in a Phase 3 study.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Keryx Biopharma (KERX) Patents Strong; JPMorgan Starts at Overweight
- Notable Analyst Rating Changes 06/19: (CX) (ADBE) (LINE) Upgraded; (CLF) (S) (BBRY) Downgraded
- SolarCity (SCTY) Files 2.8M Common Secondary; Elon Musk Plans Purchase
Create E-mail Alert Related Categories
Insider Trades
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
